All blog posts
Total 22 results for
Showing 12 out of 22 results
01 11월 2024
EU Commission fines Teva €462.6 million for misuse of divisional patents and disparagement campaign
03 10월 2024
How will the European Union develop over the next five years? Using Treaty Powers to promote Competitiveness and Security
29 7월 2024
Commission investigation into anticompetitive disparagement ends with commitments
04 7월 2024
Insights from the latest "pay-for-delay" CJEU judgments: fines on Servier and generics drug manufacturers largely upheld (but not over yet)
24 6월 2024
Overview of EU regulatory and competition law in the Pharma sector
19 2월 2024
Five Years of Activity in a Priority Sector: The European Commission's Report on Competition Enforcement in the Pharmaceutical Sector (2018-2022)
06 12월 2023
Competition law and biosimilars: Time for a new approach or not yet?
23 11월 2023
CMA issues guidance permitting drugs companies to work together on Combination Therapies
31 10월 2023
Another chapter in the "pay for delay" saga: General Court rules on the Teva-Cephalon settlement agreement
15 8월 2023
CAT upholds CMA excessive pricing decision in liothyronine tablets case
15 6월 2023
Overview of EU and South African regulatory and competition law in the Pharma sector
09 2월 2023
Competition law developments in the pharma sector – 2022 round-up and what to expect in 2023
Showing 12 out of 22 results
View moreKey contacts
Kyriakos Fountoukakos
Managing Partner, Competition Regulation and Trade, Brussels
Veronica Roberts
Partner, UK Regional Head of Practice, Competition, Regulation and Trade, London
Linda Evans
Regional Head of Practice – Competition, Regulation and Trade, Australia, Sydney
